Episodic Ataxias
The episodic ataxias (EAs) are a group of autosomal dominant channelopathies characterized by recurrent paroxysmal episodes of cerebellar dysfunction, typically with complete or near-complete interictal recovery. At least nine types have been described (EA1–EA9), though only EA1 and EA2 are common enough for robust clinical characterization. Overall prevalence is estimated at fewer than 1 per 100,000 individuals. The underlying pathophysiology involves dysfunction of ion channels or transporters expressed in cerebellar Purkinje cells and related circuits. Recognition is critical because targeted therapies — particularly 4-aminopyridine and acetazolamide — can dramatically reduce attack frequency and severity.
Bottom Line
- EA1 (KCNA1): Brief attacks (seconds to minutes) with interictal myokymia; carbamazepine preferred over acetazolamide; ~21% develop progressive cerebellar signs with long disease duration
- EA2 (CACNA1A): Most common type; prolonged attacks (hours) with interictal downbeat nystagmus; acetazolamide first-line (~50–75% respond); 4-aminopyridine has Class I RCT evidence; allelic to SCA6 and FHM1
- EAT2TREAT trial (2021): First head-to-head comparison — both fampridine (63% attack reduction) and acetazolamide (52%) significantly reduced attacks vs placebo; fampridine had fewer adverse events and was preferred by 80% of patients post-trial
- EA3–EA9: Rare types with distinct genetic, clinical, and treatment profiles; EA6 involves glutamate transporter (seizures + hemiplegia), EA8 responds to clonazepam (not acetazolamide), EA9 (SCN2A) presents with neonatal seizures preceding ataxia
- Key diagnostic clues: Attack duration, interictal findings (myokymia → EA1; downbeat nystagmus → EA2), trigger profile, and acetazolamide response all guide diagnosis before genetic confirmation
1. Episodic Ataxia Type 1 (EA1)
Genetics & Pathophysiology
| Feature | Details |
|---|---|
| Gene | KCNA1 (chromosome 12p13) |
| Protein | Kv1.1 voltage-gated potassium channel subunit |
| Inheritance | Autosomal dominant |
| Mutations | ≥28 missense mutations identified; all produce loss-of-function or dominant-negative effects on channel kinetics |
| Prevalence | ~1 in 500,000 |
| Age of onset | Mean 7.9 years; virtually all patients present before age 20 |
Clinical Features
Episodes
- Duration: Typically seconds to minutes (94% of patients); prolonged attacks lasting hours or rarely days have been documented
- Frequency: Daily (33%), weekly (27%), or monthly (39%); can occur up to 30 times per day
- Symptoms during attacks: Limb and gait ataxia, dysarthria, tremor, nystagmus, weakness; vertigo is notably less prominent than in EA2
Triggers
- Physical exertion (88%)
- Emotional stress (85%)
- Environmental temperature changes (55%)
- Startle, sudden movements, fever, caffeine, alcohol, hunger
Interictal Findings
- Myokymia is the hallmark — fine, continuous rippling of muscle visible clinically or detectable on EMG; present in nearly all patients
- Neuromyotonia confirmed on EMG in 10/12 patients studied: continuous motor unit activity with doublet, triplet, or multiplet discharges at high frequency
- Postural tremor of the head and hands may be present
Long-Term Prognosis
- ~21% develop persistent progressive cerebellar signs, correlating with longer disease duration (mean 39.8 vs 25.4 years)
- SARA scores: mean 2.0 (episodic-only) vs 7.7 (with progressive ataxia)
- Brain MRI typically normal; cerebellar atrophy is rare
- Seizures occur in ~9% (3/33 in the largest cohort)
- Attack frequency may decrease with age in untreated patients
- Quality of life: all SF-36 domain scores below population norms; mental health scoring lowest (41.3)
Treatment
- Only 36% of patients trying preventive medications report benefit
- Carbamazepine: Considered first-line; addresses both ataxia episodes and myokymia; beneficial in 3/7 patients
- Acetazolamide: Less effective than in EA2 (helpful in only 2/8 patients, ~25%)
- Other: Phenytoin and valproic acid occasionally effective; lamotrigine showed promise in limited cases
2. Episodic Ataxia Type 2 (EA2)
Genetics & Pathophysiology
| Feature | Details |
|---|---|
| Gene | CACNA1A (chromosome 19p13) |
| Protein | Cav2.1 (P/Q-type voltage-gated calcium channel α-1A subunit); highly expressed in cerebellar Purkinje cells |
| Inheritance | Autosomal dominant |
| Mutations | ~77 identified; predominantly loss-of-function (truncating, splice-site, small deletions); only ~one-third of clinically suspected cases achieve genetic confirmation |
| Prevalence | <1 per 100,000; the most common hereditary episodic ataxia |
| Age of onset | Typically first two decades (range 2–sixth decade; commonly cited as 2–32 years) |
CACNA1A Allelic Disorder Spectrum
One Gene, Three Phenotypes
CACNA1A mutations produce three distinct allelic disorders with different mechanisms:
- EA2: Loss-of-function mutations (truncating, deletions) → decreased calcium influx → episodic ataxia
- Familial Hemiplegic Migraine Type 1 (FHM1): Gain-of-function missense mutations → increased Ca2+ influx → cortical spreading depression
- SCA6: CAG trinucleotide repeat expansion in the C-terminal → late-onset progressive cerebellar ataxia
Phenotypic overlap exists within families — different members carrying the same variant may manifest EA2, FHM1, or progressive ataxia.
Clinical Features
Episodes
- Duration: Hours (typically >10 minutes, up to 2–3 days) — substantially longer than EA1
- Frequency: Variable, from four times weekly to annually
- Symptoms during attacks: Vertigo, gait and limb ataxia, nausea, vomiting, dysarthria, diplopia, weakness
- ~50% of patients meet ICHD criteria for migraine
Triggers
- Emotional stress, physical exercise, alcohol, caffeine, fever, phenytoin
Interictal Findings
- Interictal nystagmus in ~90% — downbeat nystagmus is most characteristic; gaze-evoked and rebound nystagmus also occur
- Progressive baseline ataxia develops in up to 50% over time
- Vermian cerebellar atrophy on MRI, particularly midline anterior vermis in long-standing disease
- Increased epilepsy risk, focal/segmental dystonia, cognitive deficits, tonic upward gaze (in infancy)
Treatment of EA2
Acetazolamide
- First-line therapy; ~50–75% (commonly cited as two-thirds) of patients respond
- Dosing: 250–1,000 mg/day
- Mechanism: Carbonic anhydrase inhibition; may work by altering extracellular pH and modulating calcium channel function (exact mechanism not fully elucidated)
- No RCT evidence for acetazolamide (only open-label and observational data)
- Adverse effects can be dose-limiting: paresthesias, nephrolithiasis, GI upset
- Some patients become non-responsive over time
4-Aminopyridine (4-AP) — Class I Evidence
Strupp et al. 2011 Randomized Controlled Trial
Design: Randomized, double-blind, placebo-controlled crossover trial. Two 3-month treatment periods separated by a 1-month washout.
Patients: 10 subjects (7 men), mean age 40.4 ± 16.3 years. Seven with genetically confirmed CACNA1A mutations.
Intervention: 4-aminopyridine 5 mg three times daily vs placebo.
- Attack frequency: Baseline median 10.0/month → 4-AP median 1.65/month vs placebo 6.50/month (p = 0.03); attacks reduced to 34.1% of baseline (95% CI 14.8–78.7%)
- Attack duration: Decreased from 13.65 to 4.45 hours (p = 0.08)
- Quality of life (VDADL): Improved from 6.00 to 1.50 (p = 0.022)
- Adverse effects: Minimal — nausea (2 patients), epigastric discomfort (2), palpitations (1); no discontinuations
- Long-term follow-up: 7/10 continued 4-AP at 2 years; 2 with complete attack freedom, 5 with reduced frequency/severity
Strupp M, et al. Neurology. 2011;77(3):269–275.
Mechanism of 4-Aminopyridine
4-AP blocks Kv1.5 voltage-activated potassium channels. In EA2, this restores the severely diminished precision of pacemaking in cerebellar Purkinje cells by prolonging the action potential and increasing the afterhyperpolarization. At therapeutic concentrations, 4-AP does not increase inhibitory drive of Purkinje cells (as was previously assumed) but rather restores the regularity of intrinsic Purkinje cell firing (Alvina & Bhatt, J Neurosci 2010).
EAT2TREAT Trial (2021): First Head-to-Head Comparison
Design: Phase III, randomized, double-blind, placebo-controlled, 3-period crossover trial. Each period 12 weeks with 4-week washout.
Patients: 30 EA2 patients (8 female, aged 20–71 years; 18 genetically confirmed, 4 with positive family history, 8 with clinical diagnosis).
Intervention: Fampridine 20 mg/day (10 mg BID, sustained-release) vs acetazolamide 750 mg/day (250 mg TID) vs placebo.
- Attack reduction vs placebo: Fampridine reduced attacks to 63% of placebo (95% CI 54–74%); acetazolamide to 52% (95% CI 46–60%)
- Adverse events: Fampridine 26.5% vs acetazolamide 44.9% vs placebo 28.6%
- Patient preference: Post-study, 24/30 chose to continue fampridine vs only 3/30 acetazolamide — demonstrating clear preference based on tolerability
Strupp M, et al. Neurol Clin Pract. 2021;11(5):e592–e601.
Other Agents
- Levetiracetam, dalfampridine (sustained-release 4-AP), and lamotrigine have been reported in case series with variable benefit
3. Rare Episodic Ataxias (EA3–EA9)
| Type | Gene / Locus | Onset | Episode Duration | Key Interictal Feature | AZA Response | Distinguishing Feature |
|---|---|---|---|---|---|---|
| EA3 | Unknown (1q42) | 1–42 yr | Min to 6 h | Myokymia, no nystagmus | Yes | Tinnitus + vertigo; single Canadian family |
| EA4 | Unknown | 23–60 yr | Hours | Defective smooth pursuit | No | Adult onset; two NC kindreds; gabapentin may help |
| EA5 | CACNB4 (2q22–23) | >20 yr | Hours | Downbeat + gaze-evoked nystagmus | Yes | EA2-like + seizures; single French-Canadian family |
| EA6 | SLC1A3 (5p13.2) | 5–14 yr | Hours to days | Nystagmus, progressive ataxia | Variable | EAAT1 glutamate transporter; seizures + hemiplegia |
| EA7 | Unknown (19q13) | <20 yr | Hours to days | None | Variable | Single 4-generation family (7 affected) |
| EA8 | UBR4 (1p36.13) | Infancy | Min to 24 h | Intention tremor, eyelid myokymia | No | Earliest onset; responds to clonazepam |
| EA9 | SCN2A (2q24) | 10 mo–14 yr | Min to hours | None specific | ~50% | 86% have neonatal seizures preceding ataxia |
EA6 (SLC1A3 — EAAT1 Glutamate Transporter)
SLC1A3 encodes excitatory amino acid transporter 1 (EAAT1), a glial glutamate transporter responsible for clearing extracellular glutamate to terminate neurotransmission and prevent excitotoxicity. Mutations cause decreased EAAT1 protein expression and reduced glutamate uptake capacity (e.g., the P290R mutation caused markedly reduced glutamate uptake; the C186S mutation reduced uptake by 18%). Excessive extracellular glutamate leads to neuronal hyperexcitability, explaining the associated seizures and alternating hemiplegia. Clinical heterogeneity is striking — one sporadic case showed severe EA with seizures and migraine triggered by febrile illness, while a Dutch family showed typical EA2-like symptoms.
EA9 (SCN2A — Nav1.2 Sodium Channel)
| Feature | Details |
|---|---|
| Mutation | p.A263V gain-of-function (3-fold increase in persistent sodium current) is most common, found in 7/21 patients (33%) |
| Clinical course | Biphasic: neonatal/infantile seizures (86%) → seizures remit → episodic ataxia onset (10 months–14 years) |
| Seizure characteristics | 67% start within first 3 months of life; tonic or generalized tonic-clonic; may be severe but typically remit in infancy/early childhood |
| Ataxia symptoms | Difficulty walking, dizziness, slurred speech, headache, vomiting, pain, myoclonus; every few weeks to months |
| Acetazolamide | Positive effects in ~50% (3/8 benefited; up to 30 mg/kg/day) |
| Carbamazepine | Major improvement reported in limited cases; considered second-line |
| Cognitive outcome | Favorable: 81% (17/21) with normal or mildly impaired development |
Proposed Additional Types
- FGF14-related EA (proposed EA9 by some, overlapping with SCA27): Onset childhood to adulthood; seconds to days; nystagmus + tremor; associated developmental delay and paroxysmal dyskinesia; acetazolamide-responsive; may improve with age
- CACNA1G-related EA (proposed EA10): T-type calcium channel; adult onset; unusually prolonged episodes (up to months); facial numbness, movement-induced vertigo, bilateral vestibulopathy; responds to carbamazepine; worsened by acetazolamide (important negative response)
4. Differential Diagnosis
| Category | Conditions | Key Distinguishing Features |
|---|---|---|
| Paroxysmal movement disorders | Paroxysmal kinesigenic dyskinesia (PRRT2); paroxysmal nonkinesigenic dyskinesia | Predominantly dystonic/choreiform movements rather than ataxia; very brief attacks (<1 min) in PKD |
| Vascular | Vertebrobasilar TIA | Older age, vascular risk factors; episodes do not follow trigger pattern of EA |
| Demyelinating | Multiple sclerosis (paroxysmal dysarthria and ataxia) | Stereotyped daily episodes lasting seconds to minutes; MRI shows plaques |
| Metabolic | GLUT1 deficiency (SLC2A1); maple syrup urine disease; pyruvate dehydrogenase deficiency | Often triggered by fasting/intercurrent illness; low CSF glucose in GLUT1 |
| Vestibular | Vestibular migraine; BPPV; Ménière disease | No interictal nystagmus (BPPV); positional vertigo (BPPV); hearing fluctuation (Ménière) |
| Other channelopathies | ATP1A3 (alternating hemiplegia of childhood); KCNA2; FHM2 (ATP1A2) | Hemiplegia predominant; dystonia; onset in infancy (AHC) |
| Structural | Chiari malformation type I; posterior fossa tumors | Valsalva-provoked symptoms; headache predominant; MRI diagnostic |
| Autoimmune | Anti-CASPR2; anti-NMDA receptor; Bickerstaff brainstem encephalitis | Subacute onset; positive autoantibodies; encephalopathic features |
| Functional / psychiatric | Functional neurologic disorder; anxiety/panic disorder | Inconsistency on exam; panic attacks misdiagnosed as EA; common diagnostic pitfall |
5. Diagnostic Approach
Clinical Assessment
- Detailed episode history: Age of onset, triggers, duration, frequency, associated symptoms, baseline neurologic status between episodes
- Three-generation family history
- Ictal examination if possible; video documentation of attacks
- Interictal neurologic examination focusing on:
- Myokymia (pointing toward EA1/EA3)
- Nystagmus type (downbeat/gaze-evoked → EA2; absent → EA1)
- Smooth pursuit abnormalities (EA4)
- Intention tremor and eyelid myokymia (EA8)
Investigations
| Investigation | Purpose / Findings |
|---|---|
| EMG | Essential for detecting myokymia/neuromyotonia (EA1); characteristic continuous motor unit activity with doublet/triplet discharges |
| EEG | During triggered attacks to differentiate from seizures |
| Brain MRI | Midline anterior cerebellar vermis atrophy (EA2, long-standing); normal in EA1; rules out Chiari, tumors, MS plaques |
| Metabolic/laboratory | Thyroid function, lactate/glucose (if secondary causes suspected); autoimmune markers if autoimmune ataxia considered (anti-CASPR2, anti-GAD65, anti-VGCC) |
Genetic Testing Strategy
- Classical EA1 phenotype (brief attacks + myokymia): KCNA1 single-gene testing
- Classical EA2 phenotype (prolonged attacks + nystagmus): CACNA1A single-gene testing
- Atypical or uncertain phenotype: Multigene EA panel (KCNA1, CACNA1A, CACNB4, SLC1A3, SCN2A, UBR4)
- Negative panel or complex cases: Whole-exome sequencing
- Important: Only ~one-third of clinically suspected EA2 cases achieve genetic confirmation; a negative test does not exclude EA2
Diagnostic Pearl: Acetazolamide as a Diagnostic Tool
Acetazolamide responsiveness has diagnostic value. Suspicion for an episodic ataxia should be heightened in any patient with paroxysmal cerebellar symptoms who responds to an empiric acetazolamide trial. Treatment trials can support the diagnosis while genetic testing is pending. However, non-response does not exclude EA (EA1, EA4, EA8 are acetazolamide-resistant), and response is not specific (acetazolamide also benefits some metabolic and autoimmune conditions).
6. Treatment Summary
| EA Type | First-Line | Alternative | Evidence Level |
|---|---|---|---|
| EA1 | Carbamazepine | Acetazolamide (~25% respond), phenytoin, valproate, lamotrigine | Case series / expert opinion |
| EA2 | Acetazolamide 250–1,000 mg/day or 4-aminopyridine 5 mg TID (fampridine 10 mg BID) | Levetiracetam, lamotrigine, dalfampridine | Class I RCT for 4-AP (Strupp 2011); Phase III for fampridine vs AZA (EAT2TREAT 2021) |
| EA3 | Acetazolamide | — | Single family |
| EA4 | Gabapentin (for vertigo) | Acetazolamide NOT effective | Single kindred |
| EA5 | Acetazolamide | — | Single family |
| EA6 | Variable (acetazolamide may help) | — | Two families/individuals |
| EA8 | Clonazepam | Acetazolamide NOT effective | Single report |
| EA9 | Acetazolamide (up to 30 mg/kg/day); ~50% respond | Carbamazepine; sodium channel blockers for neonatal seizures | Case series (n=21) |
| CACNA1G-related | Carbamazepine | Acetazolamide worsens symptoms | Case reports |
7. Key Distinguishing Features at a Glance
| Feature | EA1 | EA2 |
|---|---|---|
| Gene | KCNA1 (K+ channel) | CACNA1A (Ca2+ channel) |
| Attack duration | Seconds to minutes | Hours |
| Vertigo | Uncommon | Prominent |
| Interictal myokymia | Present (hallmark) | Absent |
| Interictal nystagmus | Uncommon | ~90% (downbeat) |
| Cerebellar atrophy on MRI | Rare | Common (vermian) |
| Progressive ataxia | ~21% (with long duration) | ~50% |
| Migraine association | Uncommon | ~50% |
| Acetazolamide response | Poor (~25%) | Good (50–75%) |
| Preferred treatment | Carbamazepine | Acetazolamide or 4-AP |
References
- Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77(3):269–275.
- Strupp M, Schöberl F, Grill E, et al. Fampridine and acetazolamide in EA2 and related familial EA: a prospective randomized placebo-controlled trial (EAT2TREAT). Neurol Clin Pract. 2021;11(5):e592–e601.
- Alvina K, Bhatt S. Therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci. 2010;30(21):7258–7268.
- D’Adamo MC, Hasan S, Bhatt DK, et al. Episodic ataxia type 1 (EA1): clinical characterization, quality of life and genotype-phenotype correlation. Brain. 2014;138(Pt 4):1067–1078.
- Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci. 2008;1142:250–253.
- Riant F, Vahedi K, Tournier-Lasserve E. Hereditary episodic ataxia. Rev Neurol. 2011;167(5):401–407.
- Maas RPPWM, Schieving JH, Kamsteeg EJ, et al. Episodic ataxias: primary and secondary etiologies, treatment, and classification approaches. Tremor Other Hyperkinet Mov. 2023;13:9.
- Schwarz N, Bast T, Gaily E, et al. Clinical and genetic spectrum of SCN2A-associated episodic ataxia. Eur J Paediatr Neurol. 2019;23(3):438–447.
- Rajakulendran S, Schorge S, Bhatt DK, et al. Episodic ataxia type 1: a neuronal potassium channelopathy. Neurotherapeutics. 2007;4(2):258–266.
- Jen JC, Wan J, Palos TP, et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. Neurology. 2005;65(4):529–534.
- Steckley JL, Ebers GC, Cader MZ, et al. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology. 2001;57(8):1499–1502.
- Conti V, Bhatt DK, Bhatt S, et al. De novo mutations in the gene encoding the ubiquitin-protein ligase E3 component n-recognin 4 (UBR4) cause a novel EA8. Hum Mutat. 2015;36(12):1126–1131.
- Escayg A, De Waard M, Lee DD, et al. Coding and noncoding variation of the human calcium-channel β4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet. 2000;66(5):1531–1539.
- Baloh RW. Episodic ataxias 1 and 2. In: Subramony SH, Dürr A, eds. Handbook of Clinical Neurology. Vol 103. Elsevier; 2012:595–602.
- Continuum (Minneap Minn). Ataxia. 2025;31(1):185–216.